BR0115132A - Perfis mutacionais em transcriptase reversa de hiv-1 correlacionados com resistência à droga fenotìpica - Google Patents

Perfis mutacionais em transcriptase reversa de hiv-1 correlacionados com resistência à droga fenotìpica

Info

Publication number
BR0115132A
BR0115132A BR0115132-0A BR0115132A BR0115132A BR 0115132 A BR0115132 A BR 0115132A BR 0115132 A BR0115132 A BR 0115132A BR 0115132 A BR0115132 A BR 0115132A
Authority
BR
Brazil
Prior art keywords
hiv
reverse transcriptase
mutational
drug
drug resistance
Prior art date
Application number
BR0115132-0A
Other languages
English (en)
Inventor
Pascale Alfons Rosa Dehertogh
Kurt Hertogs
Brendan Larder
Dechao Wang
Original Assignee
Virco Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virco Bvba filed Critical Virco Bvba
Publication of BR0115132A publication Critical patent/BR0115132A/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"PERFIS MUTACIONAIS EM TRANSCRIPTASE REVERSA DE HIV-1 CORRELACIONADOS COM RESISTêNCIA à DROGA FENOTìPICA". A invenção refere-se a novas mutações, combinações de mutações ou perfis mutacionais de transcriptase reversa de HIV-1 e/ou genes de protease com resistência fenotípica a drogas de HIV. Mais particularmente, a presente invenção refere-se ao uso de caracterização genotípica de uma população alvo de HIV e a correlação subseq³ente, desta informação a interpretação fenotípica a fim de correlacionar perfis mutacionais de vírus com resistência a droga. A invenção também refere-se a métodos de utilização dos perfis mutacionais da invenção em base de dados, desenvolvimento de droga, isto é, planejamento de droga, e modificação droga, planejamento de terapia e tratamento, emprego clínico e análise diagnóstica.
BR0115132-0A 2000-10-20 2001-10-22 Perfis mutacionais em transcriptase reversa de hiv-1 correlacionados com resistência à droga fenotìpica BR0115132A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24180100P 2000-10-20 2000-10-20
US24184400P 2000-10-20 2000-10-20
PCT/EP2001/012338 WO2002033638A2 (en) 2000-10-20 2001-10-22 Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance

Publications (1)

Publication Number Publication Date
BR0115132A true BR0115132A (pt) 2004-06-15

Family

ID=26934586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115132-0A BR0115132A (pt) 2000-10-20 2001-10-22 Perfis mutacionais em transcriptase reversa de hiv-1 correlacionados com resistência à droga fenotìpica

Country Status (9)

Country Link
US (2) US20040073378A1 (pt)
EP (1) EP1356082A2 (pt)
JP (1) JP2004512032A (pt)
AU (2) AU2631602A (pt)
BR (1) BR0115132A (pt)
CA (1) CA2425807A1 (pt)
MX (1) MXPA03003476A (pt)
RU (1) RU2318213C2 (pt)
WO (1) WO2002033638A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01012270A (es) * 1999-05-28 2003-06-24 Virco Nv Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos.
WO2004003223A2 (en) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
WO2004003817A1 (en) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
FR2869045A1 (fr) * 2004-04-16 2005-10-21 Bioalliance Pharma Sa Methode d'etude de la variabilite genetique et fonctionnelle du vih et kit pour sa mise en oeuvre
US20080293038A1 (en) * 2005-05-27 2008-11-27 Parkin Neil T Method for Determining Resistance of Hiv to Nucleoside Reverse Transcriptase Inhibitor Treatment
JP5297814B2 (ja) * 2006-02-03 2013-09-25 ビルコ・ビーブイビーエイ 量的ｈｉｖ表現型又は向性アッセイ

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234186A (en) 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
EP0428000A1 (en) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogenic substrates for the detection of proteolytic enzyme activity
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
WO1993023574A1 (en) 1992-05-14 1993-11-25 Kozal Michael J Polymerase chain reaction assays for monitoring antiviral therapy
US6063562A (en) * 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
ES2177922T3 (es) 1996-01-26 2002-12-16 Virco Bvba Metodo de valoracion la quimioterapia de pacientes hiv-positivos basado en la sensibilidad fenotipica a los farmacos de las cepas de hiv delpaciente.
EP0817866A1 (en) * 1996-01-26 1998-01-14 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
RO118887B1 (ro) 1996-01-29 2003-12-30 Virologic, Inc. Metodă pentru determinarea sensibilităţii sau eficacităţii biologice şi rezistenţei omului la medicamentele antivirale
JP3062459B2 (ja) 1996-08-14 2000-07-10 理化学研究所 ポリエステル重合酵素遺伝子及びポリエステルの製造方法
BR9911600A (pt) 1998-05-26 2001-02-13 Virologic Inc Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo
WO1999061666A1 (en) 1998-05-28 1999-12-02 Visible Genetics Inc. Use of polymorphisms as a predictor of drug-resistance mutations
PT1088098E (pt) 1998-06-23 2011-05-25 Univ Illinois Medicamento para tratar mam?feros infectados com hiv
US6803187B1 (en) * 1998-06-24 2004-10-12 Innogenetics N.V. Method for detection of drug-selected mutations in the HIV protease gene
CA2341679A1 (en) 1998-06-24 1999-12-29 Virologic, Inc. Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
MXPA01012270A (es) 1999-05-28 2003-06-24 Virco Nv Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos.
WO2000078996A1 (en) 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU5883300A (en) 1999-06-23 2001-01-09 Penn State Research Foundation, The Compositions and methods for the quantification of sterol biosynthetic flux
ES2373488T3 (es) 2000-04-18 2012-02-06 Virco Bvba Métodos para medir la resistencia a los fármacos frente a hcv.
EP1276909B1 (en) 2000-04-20 2013-11-13 Janssen Diagnostics BVBA Method for mutation detection in hiv using pol sequencing
CA2415832C (en) * 2000-06-08 2012-07-24 Brendan Larder Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
US7058616B1 (en) * 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
CA2422815A1 (en) 2000-09-15 2002-03-21 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
ATE422049T1 (de) 2000-10-20 2009-02-15 Virco Bvba Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz
JP2002199890A (ja) 2000-10-23 2002-07-16 Inst Of Physical & Chemical Res 生分解性ポリエステル合成酵素の改変方法
IL155780A0 (en) 2000-11-10 2003-12-23 Bioalliance Pharma Novel method for analysing phenotypic characteristics of human imunodeficiency virus (hiv)
IL157171A0 (en) 2001-02-14 2004-02-08 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino) -benzothiazole sulfonamide hiv protease inhibitors
WO2004003223A2 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
WO2004003817A1 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
US20050214744A1 (en) 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
CN1732161A (zh) 2002-09-06 2006-02-08 艾伦药物公司 1,3－二氨基－2－羟基丙烷前体药物衍生物
EP1605064A1 (en) 2004-06-07 2005-12-14 UMC Utrecht Holding B.V. HIV Variant showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant virus

Also Published As

Publication number Publication date
MXPA03003476A (es) 2004-09-10
US8574831B2 (en) 2013-11-05
AU2002226316B2 (en) 2008-06-26
CA2425807A1 (en) 2002-04-25
RU2318213C2 (ru) 2008-02-27
US20040073378A1 (en) 2004-04-15
US20080286754A1 (en) 2008-11-20
JP2004512032A (ja) 2004-04-22
WO2002033638A2 (en) 2002-04-25
WO2002033638A3 (en) 2003-08-21
EP1356082A2 (en) 2003-10-29
AU2631602A (en) 2002-04-29

Similar Documents

Publication Publication Date Title
BR0011555A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
Finkle et al. Diazepam and drug-associated deaths: a survey in the United States and Canada
Kaplowitz Causality assessment versus guilt–by–association in drug hepatotoxicity
DK0836485T3 (da) Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
BR0115132A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionados com resistência à droga fenotìpica
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
Cummings et al. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis
DE60327768D1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
Sjogren et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin
Aird et al. A study of the relative precision of acupoint location methods
Spector Neuroimmunomodulation: A brief review: Can conditioning of natural killer cell activity reverse cancer and/or aging?
DE60321466D1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
BR0110512A (pt) Preparação para medir a taxa de esvaziamento gástrico
Geller et al. Women of color: Integrating ethnic and gender identities in psychotherapy
Grobéty et al. The influence of spatial irregularity upon radial-maze performance in the rat
ATE375400T1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
CY1105624T1 (el) Αντιγλαυκωματικο μεσο και χρηση αυτου
Tuberculosis Trials Consortium The Tuberculosis Trials Consortium: a model for clinical trials collaborations.
Pishkin et al. A comparative study of the factorial composition of responses on the life style analysis across clinical groups
Johnson et al. The readability of HIV/AIDS educational materials targeted to drug users.
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
Brooks et al. Motor neurone disease: Basic designs, sample sizes and pitfalls
Radovanovic et al. Upper urothelial tumours and the Balkan nephropathy: Inference from the Study of a Family Pedigree
唐金龙 The White Cells
Maletta Use of benzodiazepines in elderly patients

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]